Gastroduodenal Pancreas Surgery Department, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University.
Tohoku J Exp Med. 2023 Aug 11;260(4):305-314. doi: 10.1620/tjem.2023.J042. Epub 2023 May 25.
Protein kinase D1 (PKD1) controls tumor growth and invasion of gastrointestinal tract-related cancers, but its prognostic role in colorectal cancer (CRC) is not clear yet. Therefore, this research intended to assess the potential of PKD1 as a marker for CRC patients' management, also to evaluate its effect on 5-fluorouracil (5-FU) chemosensitivity in CRC cell lines. PKD1 protein and mRNA expressions were measured by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction assays in 214 CRC patients, respectively. The PKD1 overexpression plasmids and negative control (NC) plasmids were transfected into the HCT-116 and LoVo cell lines followed by 0-16 μM 5-FU treatment. PKD1 protein (P < 0.001) and mRNA expressions (P < 0.001) were both descended in tumor tissues compared to tumor-adjacent tissues. Meanwhile, tumor PKD1 protein and mRNA expressions were both negatively related to lymph node metastasis, N stage, and tumor-node-metastasis (TNM) stage (all P < 0.05). Prognostically, high expressions of PKD1 protein and mRNA were linked with prolonged disease-free survival (DFS) and overall survival (OS) (all P < 0.05). After adjustment by multivariate Cox analyses, PKD1 mRNA high expression independently forecasted longer DFS [hazard ratio (HR) = 0.199, P = 0.002] and OS (HR = 0.212, P = 0.022). In vitro experiments revealed that PKD1 overexpression decreased the half maximal inhibitory concentration value of 5-FU in the HCT-116 (P = 0.016) and LoVo (P = 0.007) cell lines. PKD1 expression links with less lymph node metastasis risk and satisfied prognosis in CRC patients, which promotes CRC cell chemosensitivity to 5-FU chemosensitivity as well.
蛋白激酶 D1(PKD1)控制胃肠道相关癌症的肿瘤生长和侵袭,但它在结直肠癌(CRC)中的预后作用尚不清楚。因此,本研究旨在评估 PKD1 作为 CRC 患者管理标志物的潜力,并评估其对 CRC 细胞系中 5-氟尿嘧啶(5-FU)化疗敏感性的影响。通过免疫组织化学和逆转录定量聚合酶链反应检测 214 例 CRC 患者的 PKD1 蛋白和 mRNA 表达。将 PKD1 过表达质粒和阴性对照(NC)质粒转染到 HCT-116 和 LoVo 细胞系中,然后用 0-16 μM 5-FU 处理。肿瘤组织中 PKD1 蛋白(P<0.001)和 mRNA 表达(P<0.001)均低于肿瘤相邻组织。同时,肿瘤 PKD1 蛋白和 mRNA 表达均与淋巴结转移、N 分期和肿瘤-淋巴结-转移(TNM)分期呈负相关(均 P<0.05)。预后方面,PKD1 蛋白和 mRNA 高表达与无病生存(DFS)和总生存(OS)延长相关(均 P<0.05)。多因素 Cox 分析调整后,PKD1 mRNA 高表达独立预测 DFS 更长[风险比(HR)=0.199,P=0.002]和 OS(HR=0.212,P=0.022)。体外实验显示,PKD1 过表达降低了 HCT-116(P=0.016)和 LoVo(P=0.007)细胞系中 5-FU 的半数最大抑制浓度值。PKD1 表达与 CRC 患者的淋巴结转移风险降低和预后良好相关,同时也促进 CRC 细胞对 5-FU 化疗的敏感性。